Start Date
January 31, 2016
Primary Completion Date
July 31, 2017
Study Completion Date
October 31, 2017
NK-104-CR
NK-104-CR 8 mg daily for 52 weeks
Placebo
Placebo daily for 12 weeks
Livalo
Livalo® IR daily from week 12 to week 52
Beverly Hills
Chino
Lincoln
Los Angeles
Newport Beach
North Hollywood
Thousand Oaks
Vista
Brooksville
Fort Lauderdale
Jacksonville
Jupiter
Miami
Pembroke Pines
Port Orange
Marietta
Meridian
Chicago
Evanston
Evansville
Indianapolis
Newton
Wichita
Auburn
Elkridge
Edina
Jackson
Butte
Las Vegas
Berlin
Endwell
Rochester
Greensboro
Cincinnati
Kettering
Lyndhurst
Marion
Willoughby Hills
Downingtown
Charleston
Mt. Pleasant
Kingsport
Houston
Hurst
Madison
Lead Sponsor
Kowa Research Institute, Inc.
INDUSTRY